- Home
- RPRX vs GRAB Comparison
RPRX vs GRAB Comparison
Compare RPRX & GRAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- GRAB
- Stock Information
- Founded
- RPRX 1996
- GRAB 2012
- Country
- RPRX United States
- GRAB Singapore
- Employees
- RPRX N/A
- GRAB N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- GRAB Business Services
- Sector
- RPRX Health Care
- GRAB Consumer Discretionary
- Exchange
- RPRX Nasdaq
- GRAB Nasdaq
- Market Cap
- RPRX 16.2B
- GRAB 23.0B
- IPO Year
- RPRX 2020
- GRAB N/A
- Fundamental
- Price
- RPRX $39.69
- GRAB $5.94
- Analyst Decision
- RPRX Strong Buy
- GRAB Buy
- Analyst Count
- RPRX 3
- GRAB 8
- Target Price
- RPRX $46.00
- GRAB $6.23
- AVG Volume (30 Days)
- RPRX 3.5M
- GRAB 55.2M
- Earning Date
- RPRX 11-05-2025
- GRAB 11-04-2025
- Dividend Yield
- RPRX 2.26%
- GRAB N/A
- EPS Growth
- RPRX N/A
- GRAB N/A
- EPS
- RPRX 1.75
- GRAB 0.02
- Revenue
- RPRX $2,349,844,000.00
- GRAB $3,228,000,000.00
- Revenue This Year
- RPRX $36.16
- GRAB $24.20
- Revenue Next Year
- RPRX $2.04
- GRAB $19.57
- P/E Ratio
- RPRX $22.24
- GRAB $292.68
- Revenue Growth
- RPRX 3.70
- GRAB 20.18
- 52 Week Low
- RPRX $24.05
- GRAB $3.36
- 52 Week High
- RPRX $41.24
- GRAB $6.62
- Technical
- Relative Strength Index (RSI)
- RPRX 62.61
- GRAB 52.51
- Support Level
- RPRX $38.39
- GRAB $5.45
- Resistance Level
- RPRX $41.24
- GRAB $6.24
- Average True Range (ATR)
- RPRX 1.20
- GRAB 0.26
- MACD
- RPRX 0.18
- GRAB -0.01
- Stochastic Oscillator
- RPRX 71.36
- GRAB 63.64
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About GRAB Grab Holdings Limited
Founded in 2012, Grab provides ride-sharing services, food and grocery delivery, and financial services (payments, consumer loans, and enterprise offerings) in eight Southeast-Asian countries through its mobile platform. The company partners with merchants and riders, connecting them with consumers while charging commission to both sides. Grab has a leading market share in and derives 89% of its revenue from its core businesses, ride-sharing and food delivery. Singapore, Indonesia, and Malaysia contributed more than 70% of revenue in 2024. Grab's main competitors in Southeast Asia are Line Man and Goto. Its financial services business is still in its nascent stage and provides minimal revenue currently. The company now also generates advertising revenue.